MAIA Biotechnology, Inc. (MAIA)
MAIA moved a median of 0.00% 30 minutes after news, and -0.82% by the close. How MAIA actually reacts to news — the realized, point-in-time move the market made, measured across 397 labeled events over the last three years with zero look-ahead.
MAIA’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 49% | 395 |
| 30-min | 0.00% | 48% | 396 |
| 60-min | 0.00% | 49% | 396 |
| to close | -0.82% | 41% | 396 |
| Middle 50% of MAIA reactions | -2.16% to +1.87% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 397 |
Half of all MAIA Biotechnology, Inc. news events land between -2.16% and +1.87% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when MAIA moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to MAIA's baseline. Nothing else.
Recent MAIA events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form EFFECT MAIA Biotechnology, Inc. | SEC filing · Form EFFECT | SEC EDGAR | +0.81% | +0.85% | |
| MAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung Cancer | Press release | GlobeNewswire | +0.81% | +0.85% | |
| Form 8-K MAIA Biotechnology, Inc. For: Oct 06 | SEC filing · Form 8-K | SEC EDGAR | -0.83% | -0.83% | |
| Form S-3 MAIA Biotechnology, Inc. | SEC filing · Form S-3 | SEC EDGAR | -2.03% | -4.07% | |
| MAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal | Press release | GlobeNewswire | +0.00% | -2.22% | |
| MAIA Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancer | Press release | GlobeNewswire | +0.00% | +3.01% | |
| MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial | Press release | GlobeNewswire | +0.00% | +3.70% | |
| MAIA Biotechnology Announces Open Market Purchases of Company Stock by Long-Standing Board Member and CEO | Press release | GlobeNewswire | +2.11% | -5.63% | |
| MAIA Biotechnology Delivers Oral and Poster Presentations Showcasing Next-Generation Telomere-Targeting Cancer Therapies at IRT 2026 | Press release | GlobeNewswire | -2.21% | -3.68% | |
| Form EFFECT MAIA Biotechnology, Inc. | SEC filing · Form EFFECT | SEC EDGAR | -0.38% | -1.50% | |
| Form S-3 MAIA Biotechnology, Inc. | SEC filing · Form S-3 | SEC EDGAR | -2.86% | -3.57% | |
| Form 10-Q MAIA Biotechnology, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.09% | — | |
| MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial | Press release | GlobeNewswire | -4.70% | -1.34% | |
| MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer | Press release | GlobeNewswire | +1.45% | -2.17% | |
| MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University | Press release | GlobeNewswire | +2.27% | +6.06% | |
| MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial | Press release | GlobeNewswire | +0.38% | -4.51% | |
| MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial | Press release | GlobeNewswire | -2.32% | -3.29% | |
| MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion | Press release | GlobeNewswire | -1.80% | +3.25% | |
| MAIA Biotechnology Announces Open Market Purchases by CEO and Director | Press release | GlobeNewswire | +0.70% | -4.93% | |
| MAIA Biotechnology Presents Trial in Progress Poster for Pivotal Phase 3 Clinical Trial of Novel Telomere Targeting Agent at 2026 Annual Meeting of American Society of Clinical Oncology | Press release | GlobeNewswire | -1.44% | -6.47% | |
| Form 8-K MAIA Biotechnology, Inc. For: May 21 | SEC filing · Form 8-K | SEC EDGAR | +1.60% | +2.40% | |
| Form DEFA14A MAIA Biotechnology, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -2.40% | -1.60% | |
| Form 8-K MAIA Biotechnology, Inc. For: May 14 | SEC filing · Form 8-K | SEC EDGAR | -1.50% | -5.26% | |
| Form 10-Q MAIA Biotechnology, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +3.10% | +1.55% | |
| Form DEFA14A MAIA Biotechnology, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | -0.80% | |
| Form 8-K MAIA Biotechnology, Inc. For: Apr 16 | SEC filing · Form 8-K | SEC EDGAR | +2.12% | -5.67% | |
| MAIA Biotechnology Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced Non-Small Cell Lung Cancer | Press release | GlobeNewswire | -0.37% | -1.84% | |
| Form 8-K MAIA Biotechnology, Inc. For: Apr 08 | SEC filing · Form 8-K | SEC EDGAR | +0.40% | +0.00% | |
| MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy | Press release | GlobeNewswire | +0.40% | +0.00% | |
| Form ARS MAIA Biotechnology, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +1.70% | +2.13% | |
| Form DEF 14A MAIA Biotechnology, Inc. For: May 21 | SEC filing · Form DEF | SEC EDGAR | +0.00% | +2.13% | |
| Form DEFA14A MAIA Biotechnology, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | +2.13% | |
| Form S-8 MAIA Biotechnology, Inc. | SEC filing · Form S-8 | SEC EDGAR | +0.40% | +0.00% | |
| Form 8-K MAIA Biotechnology, Inc. For: Mar 27 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.77% | |
| Form 8-K MAIA Biotechnology, Inc. For: Mar 31 | SEC filing · Form 8-K | SEC EDGAR | +2.26% | +5.26% | |
| MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer | Press release | GlobeNewswire | +2.26% | +5.26% | |
| Form 8-K MAIA Biotechnology, Inc. For: Mar 27 | SEC filing · Form 8-K | SEC EDGAR | +1.42% | -7.09% | |
| Form 10-K MAIA Biotechnology, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | +2.06% | |
| Form 8-K MAIA Biotechnology, Inc. For: Mar 02 | SEC filing · Form 8-K | SEC EDGAR | -1.91% | -2.55% | |
| MAIA Biotechnology Announces Closing of $30 Million Underwritten Public Offering of Common Stock | Press release | GlobeNewswire | -1.91% | -2.55% | |
| MAIA Biotechnology Announces Pricing of $30 Million Underwritten Public Offering of Common Stock | Press release | GlobeNewswire | -2.09% | -1.31% | |
| MAIA Biotechnology Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants | Press release | GlobeNewswire | -2.09% | -1.31% | |
| Form 8-K MAIA Biotechnology, Inc. For: Feb 24 | SEC filing · Form 8-K | SEC EDGAR | +0.47% | +13.62% | |
| MAIA Biotechnology’s Phase 3 Momentum Demonstrates Potential Breakthrough Anticancer Opportunity in $50 Billion Immunotherapy Market | Press release | GlobeNewswire | +0.47% | +13.62% | |
| Form 8-K MAIA Biotechnology, Inc. For: Jan 20 | SEC filing · Form 8-K | SEC EDGAR | -2.27% | +6.36% | |
| MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines Targeted 2026 Clinical Milestones and Growth Momentum | Press release | GlobeNewswire | +4.50% | +10.00% | |
| Form 8-K MAIA Biotechnology, Inc. For: Jan 13 | SEC filing · Form 8-K | SEC EDGAR | +0.14% | +10.00% | |
| Form D MAIA Biotechnology, Inc. | SEC filing · Form D | SEC EDGAR | +2.69% | +2.69% | |
| MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings | Press release | GlobeNewswire | -1.42% | +4.96% | |
| Form 8-K MAIA Biotechnology, Inc. For: Dec 16 | SEC filing · Form 8-K | SEC EDGAR | +1.24% | -4.96% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the MAIA section they belong to.
Where else MAIA is measured.
MAIA earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is MAIA Biotechnology, Inc.'s median reaction calculated?
Every labeled MAIA news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 397 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 48% of MAIA's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does MAIA's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.